Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo Capsules

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44399   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    360 result(s) found for: Placebo Capsules. Displaying page 15 of 18.
    «« First « Previous 10  11  12  13  14  15  16  17  18  Next»
    EudraCT Number: 2014-001489-85 Sponsor Protocol Number: FRM-0334-002 Start Date*: 2015-02-23
    Sponsor Name:FORUM Pharmaceuticals Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects wit...
    Medical condition: Prodromal to Moderate Frontotemporal Dementia with Granulin Mutation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) IT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003293-25 Sponsor Protocol Number: DIM05 Start Date*: 2007-11-20
    Sponsor Name:Medivation, Inc.
    Full Title: A MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE
    Medical condition: Huntington's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020469 Huntington's chorea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000397-30 Sponsor Protocol Number: MADE Start Date*: 2013-07-30
    Sponsor Name:King's College London [...]
    1. King's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: Minocycline in Alzheimer's disease efficacy trial:The MADE trial
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003285-26 Sponsor Protocol Number: ASTA Start Date*: Information not available in EudraCT
    Sponsor Name:Universität Mainz, Klinik und Poliklinik für Kinder- und Jugendpsychiatrie und -psychotherapie
    Full Title: Effect of methylphenidate formulation on ADHD-patients' adherence to medical treatment. A comparison of Medikinet retard® (ER) once daily and Medikinet® (IR) twice daily in children and adolescents...
    Medical condition: Effect of methylphenidate formulation on ADHD-patients adherence to treatment
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000163-89 Sponsor Protocol Number: COG0104 Start Date*: 2018-04-23
    Sponsor Name:Cognition Therapeutics, Inc.
    Full Title: A Pilot Study to Evaluate the Effect of CT1812 Treatment on Aβ Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease Followed by a Six-Month Open Label Extension of a...
    Medical condition: Sponsor is developing an oral formulation of CT1812 fumarate to treat AD and mild cognitive impairment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002812-36 Sponsor Protocol Number: PTC743-NEU-003-FA Start Date*: 2021-02-18
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: A Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich ataxia (MOVE-FA)
    Medical condition: Friedreich Ataxia (FA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10017374 Friedreich's ataxia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003191-21 Sponsor Protocol Number: CK-LX3430 Start Date*: 2009-08-20
    Sponsor Name:Cardiokine Biopharma, LLC
    Full Title: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects with Euvolemic Hyponatremia
    Medical condition: Euvolemic hyponatremia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021038 Hyponatremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) IT (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004574-17 Sponsor Protocol Number: CC-220-SLE-002 Start Date*: 2017-06-08
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
    Medical condition: SYSTEMIC LUPUS ERYTHEMATOSUS
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10025134 Lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Completed) DE (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004276-21 Sponsor Protocol Number: I3Y-MC-JPCM Start Date*: 2019-01-02
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2/3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer
    Medical condition: Metastatic Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Trial now transitioned) DE (Restarted) GB (Completed) NL (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001851-11 Sponsor Protocol Number: LRP/LND101001/2013/001 Start Date*: 2015-06-19
    Sponsor Name:Lupin Atlantis Holdings S.A.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group, Comparative, Multicenter, Phase 2 Clinical Study to Evaluate Efficacy and Safety of Two Doses of LND101001 Monotherapy in Patients wi...
    Medical condition: Mild to Moderate Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) LT (Prematurely Ended) PL (Completed) IT (Completed) ES (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002385-23 Sponsor Protocol Number: AFT-MXCF-03 Start Date*: 2015-11-10
    Sponsor Name:AFT Pharmaceuticals Ltd
    Full Title: A phase 3 randomised, double blind, multiple dose, parallel group efficacy study of different doses of phenylephrine hydrochloride combined with paracetamol and/or ibuprofen in participants with na...
    Medical condition: nasal congestion
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028735 Nasal congestion PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000739-15 Sponsor Protocol Number: B4Z-US-LYEB Start Date*: 2021-12-02
    Sponsor Name:Eli Lilly and Company
    Full Title: A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia
    Medical condition: Attention-Deficit/Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-002815-10 Sponsor Protocol Number: C0168T67 Start Date*: 2005-05-04
    Sponsor Name:Centocor B.V.
    Full Title: Multicenter, Randomized, Double-Blind, Active-Controlled Trial Comparing REMICADE® (infliximab) and REMICADE® plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn’s Disease Nai...
    Medical condition: moderate to severe Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    7.1 10011401
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) DE (Completed) GB (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-019858-41 Sponsor Protocol Number: CR100101/CO15570 Start Date*: 2011-02-09
    Sponsor Name:Avraham Pharmaceuticals Ltd.
    Full Title: A 6-month prospective, multi-center, double-blind, placebo-controlled, randomized, adaptive-trial-design study to evaluate the safety and efficacy of 80mg b.i.d. ladostigil in patients with mild to...
    Medical condition: Patient with mild to moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-004276-49 Sponsor Protocol Number: CD-LAQ-201 Start Date*: 2008-09-16
    Sponsor Name:Teva Pharmaceutical Industries Ltd.
    Full Title: Estudio de fase IIa, multicéntrico, randomizado, doble ciego, controlado con placebo, de cohortes secuenciales, de búsqueda de rango de dosis para evaluar la seguridad, tolerabilidad y el efecto cl...
    Medical condition: Enfermedad de Crohn activa de moderada a grave
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003204-40 Sponsor Protocol Number: PATHBP_2013 Start Date*: 2014-01-20
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Paracetamol treatment in hypertension: effect on blood pressure
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10005729 Blood pressure ambulatory PT
    14.1 10047065 - Vascular disorders 10020775 Hypertension arterial LLT
    14.1 10022891 - Investigations 10005756 Blood pressure systolic PT
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    14.1 10022891 - Investigations 10005735 Blood pressure diastolic PT
    14.1 10022891 - Investigations 10033762 Paracetamol LLT
    14.1 10022891 - Investigations 10005727 Blood pressure PT
    14.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-005060-18 Sponsor Protocol Number: 2016AL002 Start Date*: 2018-03-09
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: The Role of Uric Acid Metabolism in Pathogenesis of Anaphylaxis: the Effect of Allopurinol on Experimentally-induced Allergic Reaction to Peanut in Peanut Allergic Adults- a randomised, double-blin...
    Medical condition: Determination of the Lowest Observed Adverse Event level dose (LOAEL)of peanut in individual suffering with peanut allergy, after treatment with allopurinol.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001738 Allergy LLT
    20.0 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2009-018070-64 Sponsor Protocol Number: 28431754DIA3012 Start Date*: 2010-05-12
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26 Week Multicenter Study with a 26-Week Extension to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 (Canagli...
    Medical condition: Type 2 Diabetes Mellitus With Inadequate Glycemic Control
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) DE (Completed) PT (Prematurely Ended) FR (Completed) ES (Completed) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005450-23 Sponsor Protocol Number: MS-LAQ-302 Start Date*: 2008-03-17
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad...
    Medical condition: Esclerosis Múltiple Remitente Recurrente (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) EE (Completed) CZ (Completed) IT (Completed) SK (Completed) LT (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004334-41 Sponsor Protocol Number: LAQ/5063OL Start Date*: 2006-02-10
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: An active extension of LAQ/5062 study. A multinational, multicenter, randomized, double-blind, parallel-group study, to evaluate the safety, tolerability and efficacy of two doses (0.3 mg and 0.6 m...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) ES (Completed) DE (Completed) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 10  11  12  13  14  15  16  17  18  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 12 04:49:01 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA